Search the Newsreel

Crinetics Pharmaceuticals (CRNX) Reports Q2 2026 Results, Is The Stock About Right?

ARS Pharmaceuticals (SPRY) Stock Faces Margin Squeeze As Losses Deepen

How New Mexico’s $567 Million Ruling Could Change Meta

A New Mexico judge has imposed Meta Platforms, Inc. (NASDAQ:META)'s highest single penalty yet in the wave of litigation over social media's effects on children, and while the monetary amount is making headlines, the more important aspect of the verdict may be what it …

Walleye Capital LLC Invests $4.84 Million in Xeris Biopharma Holdings, Inc. $XERS

Walleye Capital LLC has invested $4.84 million in Xeris Biopharma Holdings, Inc. by acquiring 611,296 shares in the second quarter, representing 0.35% of the company. Institutional investors collectively own 42.75% of Xeris. Despite reporting higher-than-expected revenue of $92.1 million, the company posted an adjusted …

Permianville: Q2 Earnings Snapshot

Permianville Royalty Trust (PVL) reported net income of $1.1 million, or 3 cents per share, for its second quarter. The Houston-based oil and gas trust also posted revenue of $14.8 million for the period. This financial report was generated using data from Zacks Investment …

Walleye Capital LLC Buys New Position in Xenon Pharmaceuticals Inc. $XENE

Walleye Capital LLC has acquired a new position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE), purchasing 76,955 shares valued at approximately $4.65 million. This move is amidst positive analyst sentiment with a "Buy" rating and a $77.13 average price target, despite recent insider stock sales totaling …

Cetera Investment Advisers Buys Shares of 15,819 Gorman-Rupp Company (The) $GRC

Cetera Investment Advisers initiated a new position in Gorman-Rupp Company, purchasing 15,819 shares valued at approximately $983,000, which represents 0.06% of the company. Institutional investors collectively own 59.26% of Gorman-Rupp. The company recently reported quarterly earnings of $0.74 per share, exceeding analyst estimates, and …

Value Partners Investments Inc. Reduces Holdings in Thermo Fisher Scientific Inc. $TMO

Thompson Investment Management Inc. Increases Stock Position in Meta Platforms, Inc. $META

Amylyx Pharmaceuticals (AMLX) Stock Trades At A Premium After Avexitide Trial Progress

Amylyx Pharmaceuticals (AMLX) stock has seen a 170.4% return over the past year, but its valuation metrics suggest it is trading at a premium. The progress of the avexitide trial, including its completed pivotal trial and potential commercial launch, supports future cash flow expectations, …

Redcare Pharmacy Aktie • A2AR94 • NL0012044747

Madrigal’s Rezdiffra Hits $1.3B Run Rate as MASH Pipeline Expands

Madrigal Pharmaceuticals' drug Rezdiffra achieved a $1.3 billion trailing-12-month revenue run rate in Q2 2026, with revenue up 71% year-over-year and over 49,000 active patients. The company is expanding its MASH pipeline to 10 assets, primarily for combination with Rezdiffra, targeting weight loss, liver-fat …

Wedge Capital Management L L P NC Buys Shares of 128,845 Theravance Biopharma, Inc. $TBPH

Wedge Capital Management L L P NC recently acquired 128,845 shares of Theravance Biopharma (NASDAQ:TBPH) worth approximately $2.19 million, now owning about 0.25% of the company. Institutional investors hold 99.10% of TBPH, despite the company reporting an adjusted loss and missing revenue expectations in …

Permian Resources (PR) Stock Still Looks Cheap On Earnings While Broader Checks Stay Mixed

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Permian Resources has delivered a very large 5 year return, yet its current checks on valuation offer a more measured read, with the …

Security National Bank Boosts Stock Position in Thermo Fisher Scientific Inc. $TMO

Security National Bank increased its stake in Thermo Fisher Scientific Inc. (TMO) by 18.5% in the second quarter, bringing its total holdings to 14,095 shares valued at approximately $7.1 million. The article also notes that institutional investors own 89.23% of TMO, and analysts generally …

Milestone’s FDA Win Now Faces A Tougher Test: Sales

Milestone Pharmaceuticals (NASDAQ: MIST) recently gained FDA approval for its lead product, CARDAMYST™ (etripamil) nasal spray, for PSVT. However, the company now faces the challenge of commercializing the product, with early sales and market sentiment being mixed. The success of CARDAMYST depends heavily on …

How Securities Lawsuits Over Trial Disclosures Will Impact Regeneron Pharmaceuticals’ (REGN) Pipeline-Driven Investment Story

Regeneron Pharmaceuticals is facing securities class action lawsuits concerning alleged misleading statements about its Phase III Fianlimab-Libtayo trial. These lawsuits, focusing on disclosure practices regarding trial delays and failure, could influence investor perception of Regeneron's pipeline-driven strategy, especially as the company advances new programs …

Brown Shipley& Co Ltd Purchases 1,857 Shares of Meta Platforms, Inc. $META

Empowered Funds LLC Buys 119,202 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR

Empowered Funds LLC significantly increased its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 661.6% in the first quarter, adding 119,202 shares to reach a total of 137,220 shares valued at $8.6 million. This move is part of a broader trend of institutional investment, with …

Cannon Advisors Inc. Acquires New Shares in Thermo Fisher Scientific Inc. $TMO

Cannon Advisors Inc. recently purchased 3,971 shares of Thermo Fisher Scientific Inc. (NYSE:TMO) valued at approximately $2.12 million, making it their 17th biggest position. This acquisition comes as other hedge funds have also adjusted their holdings in TMO, while company insiders have sold a …

Canoe Financial LP Buys 148,999 Shares of Thermo Fisher Scientific Inc. $TMO

IONS Stock Jumps 4% After-Hours — Goldman Sachs Lifts Price Target On Tryngolza Approval

Bank of America Corp DE Boosts Stake in Kiniksa Pharmaceuticals International, plc $KNSA

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Consensus Rating of "Moderate Buy" from Analysts

NRx Pharmaceuticals (NASDAQ:NRXP) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $34.50. Despite this, the company recently missed its quarterly earnings and revenue estimates. Hedge funds and institutional investors hold 4.27% of the stock.

Connect Biopharma (NASDAQ:CNTB) Upgraded by Wall Street Zen to Hold Rating

Wall Street Zen has upgraded Connect Biopharma (NASDAQ:CNTB) from a "sell" to a "hold" rating, though the broader analyst consensus remains a "Moderate Buy" with an average price target of $7.43. The company recently reported a quarterly loss of $0.27 per share, outperforming expectations, …

Vertex (VRTX) Stock Looks Above Fair Value On Earnings Yet About Right Overall

Vertex Pharmaceuticals (VRTX) has seen strong multi-year performance, with a 158.2% return over the past five years, but its current valuation suggests it's neither a clear bargain nor obviously overvalued. The stock trades at 29.1x earnings, slightly above Simply Wall St's fair P/E estimate …

ARWR Stock Clocks Best Day In Nearly 8 Months As Analyst Lifts Price Target On Plozasiran Data

How (HASI) Movements Inform Risk Allocation Models

This article analyzes Hannon Armstrong Sustainable Infrastructure Capital Inc. (NASDAQ: HASI) using AI models, indicating strong sentiment across all horizons and an exceptional 25.3:1 risk-reward setup. It outlines specific institutional trading strategies (Position Trading, Momentum Breakout, and Risk Hedging) with entry, target, and stop-loss …

Sprouts Farmers Market, Inc. (NASDAQ:SFM) Given Consensus Recommendation of "Hold" by Brokerages

Brokerages have given Sprouts Farmers Market (NASDAQ:SFM) a consensus "Hold" recommendation, with an average 12-month price target of $91.58 among 14 analysts. While the company recently exceeded earnings and revenue expectations, analysts noted softer comparable sales and margin pressure, leading to some reduced near-term …

Wall Street Zen Upgrades Regeneron Pharmaceuticals (NASDAQ:REGN) to Strong-Buy

Wall Street Zen has upgraded Regeneron Pharmaceuticals (NASDAQ:REGN) from a "buy" to a "strong-buy" rating. This upgrade follows Regeneron's strong quarterly earnings, where it surpassed analyst expectations for both EPS and revenue. Despite positive news regarding pipeline expansion and collaborations, the company faces risks …

German American Bancorp (NASDAQ:GABC) Stock Crosses Above Two Hundred Day Moving Average - What's Next?

NewAmsterdam Pharma (NAMS) Earnings Losses Raise The Question Of Whether The Stock Is A Bargain

Under Armour (UAA) Stock May Trade At A Premium On Cash Flow But A Discount On Sales

RMC Switchgears Q1 Results: Net profit up 116.8% YoY to ₹918.5 crore

Inovio Pharmaceuticals (NASDAQ:INO) Upgraded to "Hold" at Wall Street Zen

Wall Street Zen has upgraded Inovio Pharmaceuticals (NASDAQ:INO) from a "Sell" to a "Hold" rating, though overall analyst opinions remain mixed, with MarketBeat reporting a "Moderate Buy" consensus. The company recently exceeded earnings estimates, reporting a quarterly EPS of negative $0.07 against an expected …

Under Armour (UAA) Stock Looks Overvalued Relative To Fair Value

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Under Armour stock is coming off a difficult stretch, with the share price down about 77.1% over the past five years, while the valuation checks …